News
UTSA Opens New Venture Incubator to Nurture Tech Start-ups
Bio-pharmaceutical company ViroXis will be the first to move in The University of Texas at San Antonio ...
Vidacare's OnControl™ Bone Marrow System Is Quantum Leap Forward for Bone Marrow Procedures
Much-Anticipated Technology That Offers Alternative to "Barbaric" Traditional Procedures Is ...
Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
San Antonio Business Journal
The U.S. Patent and Trademark Office issued a new patent to GenSpera Inc. to cover the intellectual property on the company’s second anti-cancer drug compound currently in development.
The patent 7,635,682 covers GenSpera’s drug G-115 — which is activated in prostate tumors by an enzyme. In preclinical testing, G-115 was shown to inhibit the growth of tumors in animal models of prostate cancer. Obtaining the patent rights to this drug is key as GenSpera seeks formal Food and Drug Administration approval.
GenSpera’s President and CEO Craig Dionne says that the term of the patent will extend into 2026. This will give the company time to enter into discussions with future development partners.
San Antonio-based GenSpera is a development stage oncology company with a technology platform that delivers drugs directly into tumors.
